We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
View All

Blog - Pharmaceutical Products

Neumora Therapeutics Faces Setback as Depression Drug Trial Fails
Neumora Therapeutics Faces Setback as Depression Drug Trial Fails
Jan 2, 2025
Eye 228

Neumora Therapeutics' shares drop as navacaprant fails in a critical depression drug trial amid hopes for a successful outcome.
Uncertainty in the 2025 Weight-Loss Drug Market
Uncertainty in the 2025 Weight-Loss Drug Market
Jan 1, 2025
Eye 1263

The 2025 weight-loss drug market faces challenges with competition and supply constraints, impacting key players like Novo Nordisk and Amgen, as indicated by recent data and expert insights.
Veterinary Healthcare Industry Boom: Innovations and Trends
Veterinary Healthcare Industry Boom: Innovations and Trends
Dec 27, 2024
Eye 176

Discover how innovations in veterinary healthcare, including brain surgery and nanotechnology, are driving industry growth and changing consumer priorities.
FDA Approves Injectable Form of Bristol Myers Squibb's Opdivo
FDA Approves Injectable Form of Bristol Myers Squibb's Opdivo
Dec 27, 2024
Eye 207

Learn about FDA's approval of an injectable version of Opdivo, offering a more convenient cancer treatment option.
Pharmaceutical Giants Compete in Obesity Drug Market
Pharmaceutical Giants Compete in Obesity Drug Market
Dec 23, 2024
Eye 224

Pharmaceutical companies are fiercely competing in the obesity drug market, with Eli Lilly and Novo Nordisk among the major players. Innovations and collaborations are key in this dynamic and lucrative sector.
Novo Nordisk Shares Plummet as Weight-Loss Drug Trials Disappoint
Novo Nordisk Shares Plummet as Weight-Loss Drug Trials Disappoint
Dec 20, 2024
Eye 767

Novo Nordisk's shares plummet after CagriSema weight-loss drug trials fall short, impacting the company's market position significantly.
Merck's Experimental HIV Drug Combination Achieves Key Milestones
Merck's Experimental HIV Drug Combination Achieves Key Milestones
Dec 19, 2024
Eye 101

Merck's new HIV drug combination meets key clinical trial endpoints, offering hope for more effective HIV treatments.
Novo Holdings Completes $16.5 Billion Catalent Takeover
Novo Holdings Completes $16.5 Billion Catalent Takeover
Dec 18, 2024
Eye 66

Novo Holdings finalizes a $16.5 billion takeover of Catalent, marking a significant milestone in the pharmaceutical industry and strengthening its healthcare sector presence.
Positive Clinical Trials Propel Teva and Sanofi Shares Higher
Positive Clinical Trials Propel Teva and Sanofi Shares Higher
Dec 17, 2024
Eye 169

Teva and Sanofi shares surged as their joint clinical trial for ulcerative colitis and Crohn's disease treatment showed promising results, achieving key endpoints.
Pfizer's 2025 Revenue Projections Align with Analysts' Expectations
Pfizer's 2025 Revenue Projections Align with Analysts' Expectations
Dec 17, 2024
Eye 563

Pfizer forecasts 2025 sales between $61B-$64B, meeting Wall Street expectations, amid strategic moves like cost cuts and leadership in R&D.
Goldman Sachs Asset Management Set to Acquire Synthon International from BC Partners
Goldman Sachs Asset Management Set to Acquire Synthon International from BC Partners
Dec 15, 2024
Eye 413

Goldman Sachs Asset Management is close to acquiring Synthon International from BC Partners for around EUR2 billion, highlighting the growing interest in the pharmaceutical industry.
Novo Holdings to Finalize $16.5 Billion Acquisition of Catalent
Novo Holdings to Finalize $16.5 Billion Acquisition of Catalent
Dec 14, 2024
Eye 173

Novo Holdings finalizes $16.5 billion acquisition of Catalent, enhancing pharmaceutical capabilities amidst regulatory clearance.
Show more